Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Nabil Abadir_2023
VIEWPOINTS

Nabil Abadir, CMO and Head of Global Medical Affairs at Amarin Corp Shares Insights from New Data Evaluating Vascepa/Vazkepa at ACC.23/WCC

Shots:Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCCHe also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndromeThe interview shows how Amarin is developing innovative therapies, increasing the…
July 18, 2023

Read more

PharmaShots Interview Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results
VIEWPOINTS

PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

Shots:Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseasesThe interview summarizes…
August 3, 2022

Read more